232 related articles for article (PubMed ID: 1375867)
21. Tumour markers in patients on deferred treatment: prostate specific antigen doubling times.
Schmid HP
Cancer Surv; 1995; 23():157-67. PubMed ID: 7542562
[TBL] [Abstract][Full Text] [Related]
22. Serum keratinocyte growth factor measurement in patients with prostate cancer.
Mehta PB; Robson CN; Neal DE; Leung HY
J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
[TBL] [Abstract][Full Text] [Related]
23. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement.
Bhuiyan AK; Kibria SA; Subhan SS
Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483
[TBL] [Abstract][Full Text] [Related]
24. Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.
Marks LS; Dorey FJ; Rhodes T; Shery ED; Rittenhouse H; Partin AW; deKernion JB
J Urol; 1996 Sep; 156(3):1035-9. PubMed ID: 8709302
[TBL] [Abstract][Full Text] [Related]
25. The effect of finasteride on prostate specific antigen: review of available data.
Guess HA; Gormley GJ; Stoner E; Oesterling JE
J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
[TBL] [Abstract][Full Text] [Related]
26. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
28. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate.
Barak M; Mecz Y; Lurie A; Gruener N
J Lab Clin Med; 1989 May; 113(5):598-603. PubMed ID: 2469756
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
[TBL] [Abstract][Full Text] [Related]
31. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
[TBL] [Abstract][Full Text] [Related]
32. Analysis of NK cell activity, lymphocyte reactivity to mitogens and serotest PSA and TPS values in patients with primary and disseminated prostate cancer, PIN and BPH.
Kastelan M; Kovacić K; Tarle R; Kraljić I; Tarle M
Anticancer Res; 1997; 17(3B):1671-5. PubMed ID: 9179216
[TBL] [Abstract][Full Text] [Related]
33. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
34. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM
Cancer; 2006 Apr; 106(7):1507-13. PubMed ID: 16518812
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.
Gerber GS; Gornik HL; Goldfischer ER; Chodak GW; Rukstalis DB
J Urol; 1998 Apr; 159(4):1243-6. PubMed ID: 9507845
[TBL] [Abstract][Full Text] [Related]
36. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
Paus E; Nilsson O; Børmer OP; Fosså SD; Otnes B; Skovlund E
J Urol; 1998 May; 159(5):1599-605. PubMed ID: 9554362
[TBL] [Abstract][Full Text] [Related]
37. [Clinical assessment of free serum prostate specific antigen (PSA)].
Chautard D; Daver A; Bali B; Dardari J; Debras B; Colls P; Soret JY
Prog Urol; 1996 Jun; 6(3):368-74. PubMed ID: 8763691
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal evaluation of prostate-specific antigen levels in a case-control study.
De Biasi F; Londero D; Praturlon S; Di Donna A; Feruglio GA; Guerra UP
Eur Urol; 1996; 29(2):184-8. PubMed ID: 8647144
[TBL] [Abstract][Full Text] [Related]
39. [Anatomoclinical and biologic correlations in prostatic pathology. Apropos of 150 case reports].
Amiel J; Chevallier D; Peyrottes A; Benoliel J; Toubol J
Ann Urol (Paris); 1989; 23(6):528-30. PubMed ID: 2482700
[TBL] [Abstract][Full Text] [Related]
40. [Prostate-specific antigen in prostatic pathology].
Teillac P; Peyret C; Leroy M; Najean Y; Le Duc A
Ann Urol (Paris); 1988; 22(3):193-6. PubMed ID: 2456712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
